MEDICAL POLICY

Rhinoplasty
(All Lines of Business Except Medicare)

Effective Date: 11/1/2019
Medical Policy Committee Approved Date: 11/09; 9/17; 3/18; 3/19; 6/19; 10/19

See Policy CPT CODES section below for any prior authorization requirements

SCOPE:

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

APPLIES TO:

All lines of business except Medicare

BENEFIT APPLICATION

Medicaid Members

Oregon: Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

POLICY CRITERIA

Note: This medical policy does not address surgical treatments for rhinoplasty (with or without cleft palate repair) in patients 17 years of age or younger OR rhinoplasty in the case of acute nasal fracture/trauma, all of which may be considered medically necessary. “Acute” is defined as the emergent treatment of nasal fractures when the problem is diagnosed and a treatment plan delineated within 72 hours of the fracture/trauma.

I. Rhinoplasty for reconstructive purposes may be considered medically necessary and covered when all of the following criteria (A.-C.) are met:

A. Patient has severe nasal airway obstruction and the procedure is essential to accomplish opening of the nasal airways; and
MEDICAL POLICY

Rhinoplasty

B. Patient has one or more of the following (1.-2.):
   1. Nasal deformity; and/or
   2. History of trauma; and

C. All of the following (1.-2.) documentation is submitted:
   1. Complete otolaryngologist evaluation; and
   2. Documentation of the proposed surgical plan.

II. Rhinoplasty is considered cosmetic and not covered when criterion I. above is not been met.

Link to Policy Summary

CPT CODES

All Lines of Business Except Medicare

Prior Authorization Required

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>30400</td>
<td>Rhinoplasty, primary; lateral and alar cartilages and/or elevation of nasal tip</td>
</tr>
<tr>
<td>30410</td>
<td>Rhinoplasty, primary; complete, external parts including bony pyramid, lateral and alar cartilages, and/or elevation of nasal tip</td>
</tr>
<tr>
<td>30420</td>
<td>Rhinoplasty, primary; including major septal repair</td>
</tr>
<tr>
<td>30430</td>
<td>Rhinoplasty, secondary; minor revision (small amount of nasal tip work)</td>
</tr>
<tr>
<td>30435</td>
<td>Rhinoplasty, secondary; intermediate revision (bony work with osteotomies)</td>
</tr>
<tr>
<td>30450</td>
<td>Rhinoplasty, secondary; major revision (nasal tip work and osteotomies)</td>
</tr>
</tbody>
</table>

No Prior Authorization Required

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>30460</td>
<td>Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip only</td>
</tr>
<tr>
<td>30462</td>
<td>Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip, septum, osteotomies</td>
</tr>
</tbody>
</table>

DESCRIPTION

Per the Centers for Medicare & Medicaid Local Coverage Determination (LCD): Plastic Surgery (L37020)¹, rhinoplasty is defined as

“a procedure performed on the external or internal structures of the nose, septum, or turbinate. This surgery may be performed to improve abnormal function, reconstruct congenital or acquired deformities, or to enhance appearance. It generally involves rearrangement or excision of the supporting bony and cartilaginous structures and incision or excision of the overlying skin of the nose.”
REVIEW OF EVIDENCE

A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding the use of functional rhinoplasty. Below is a summary of the available evidence identified through August 2019.

Systematic Reviews

- In 2019, Kandathil and colleagues conducted a systematic review and meta-analysis evaluating efficacy of repair of the lateral nasal wall in adult patients with nasal airway obstruction. Independent investigators systematically searched the literature through July 2017, identified eligible studies, assessed study quality, and extracted data. Effect sizes were first calculated for each study and then pooled together using random effects synthesis. In total, 10 observational studies were included for review (8 prospective, 2 retrospective), assessing 324 participants (range: 6 to 79). Follow-up ranged from 3 months to 24 months. The pooled effect size supported the efficacy of functional rhinoplasty for the treatment of nasal airway obstruction caused by lateral nasal wall insufficiency – the pooled effect size for functional rhinoplasty was 47.7 (95% CI, -53.4 to 42.1) points on the Nasal Obstruction Symptom Evaluation scale with high heterogeneity of 72%. Outcomes were similar at short (-45.0 points [95% CI, -47.8 to -42.2 points]), mid (-48.4 points [95% CI, -52.5 to -44.4 points]), and long-term (-49.0 points [95% CI, -62.1 to -35.8 points]) follow-ups. Limitations included small sample sizes, study design, high heterogeneity (I² = 72%) and the lack of randomized or controlled trials.

- In 2017, Floyd and colleagues conducted a systematic review and meta-analysis of studies evaluating functional rhinoplasty outcomes with the Nasal Obstruction Symptom Evaluation (NOSE) score. Independent investigators systematically searched the literature through November 2015, identified eligible studies, assessed study quality, and extracted data. Study results were pooled with a random effects model; change in NOSE score after surgery was assessed with both the mean difference between baseline and postoperative results and the standardized mean difference. In total, 16 studies were included for review, assessing NOSE scores for 479 patients (range: 7 to 38). The studies’ had a pooled mean preoperative NOSE score of 67.4 (95% CI, 61-73.9) based on random effects meta-analysis. The range of scores was 34.8 to 86.5 with very high heterogeneity (I² = 95). Substantial improvement in NOSE score was reported at 3-, 6-, and 12-month follow-up. Investigators concluded that nasal obstruction, as measured by the NOSE survey, improves substantially for at least 12 months after functional rhinoplasty. Limitations undermining results’ validity included small sample sizes, high heterogeneity, the preponderance of case series included for review, inadequate follow-up, and a lack of randomized or controlled trials conducted to date.

- In 2008, Rhee and colleagues conducted a systematic review evaluating the safety and efficacy of functional rhinoplasty or nasal valve repair. Independent investigators systematically searched the literature through August 2007, identified eligible studies, assessed study quality, and extracted data. In total, 82 articles were included for review, 44 of which met inclusion criteria (42 case series, 2 cohort studies), evaluated 2,295 patients (range: 7 to 312) who had undergone some form of functional rhinoplasty. Follow-up ranged from 1 month to 13 years. Outcome measures of interest included subjective gross patient reports, non-validated questionnaires, validated patient-report measures and objective measurements (e.g.
Rhinoanometry, acoustic rhinometry, and nasal airflow studies). Limitations included heterogeneity of study design, quality, invention and outcome measures used, all of which prevented the pooling of data. Despite heterogeneity, all articles generally supported the efficacy of functional rhinoplasty techniques for the treatment of nasal obstruction. Efficacy ranged from 65% to 100%, with no study finding rhinoplasty ineffective as an intervention. Investigators concluded that there was substantial level 4 evidence (i.e. case series/case report) to support the efficacy of rhinoplasty techniques for treatment of nasal obstruction due to nasal valve collapse. Authors also called for additional studies using comparison cohorts and standardized objective outcome measures to further establish the efficacy of rhinoplasty.

**CLINICAL PRACTICE GUIDELINES**

No relevant clinical practice guidelines were identified addressing the use of functional rhinoplasty for the treatment of nasal obstruction.

**POLICY SUMMARY**

Data from systematic reviews of case series indicate that rhinoplasty is a safe and effective treatment of nasal obstruction. Despite limitations arising from studies’ small sample sizes, case series design and high heterogeneity, meta-analyses suggest that rhinoplasty significantly improves patients’ Nasal Obstruction Symptom Evaluation (NOSE) score, an important patient-reported outcome. While randomized and controlled trials with larger patient cohorts are necessary to further establish validity, especially of objective outcomes measures, long-term data from low-quality studies sufficiently demonstrates the procedure’s efficacy.

**INSTRUCTIONS FOR USE**

Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Companies reserve the right to determine the application of Medical Policies and make revisions to Medical Policies at any time. Providers will be given at least 60-days’ notice of policy changes that are restrictive in nature.

The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement.

**REGULATORY STATUS**

*Mental Health Parity Statement*

Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case.
MEDICAL POLICY CROSS REFERENCES

- Cosmetic and Reconstructive Procedures (All Lines of Business Except Medicare), SUR193
- Cosmetic and Reconstructive Procedures (Medicare Only), SUR441
- Rhinoplasty (Medicare Only), SUR444

REFERENCES


